

Special Issue

Molecular Mechanisms of Antibiotic Resistance in *Staphylococcus aureus*

Message from the Guest Editors

With a post-antibiotic era fast approaching, the rapid rise of AMR has now become one of the greatest threats to human health. *Staphylococcus aureus* is particularly concerning as it has both an arsenal of virulence factors as well as the ability to acquire resistance to most antibiotics. Elucidating the molecular mechanisms behind these complex resistance phenotypes is crucial for novel therapeutic strategies that can circumvent AMR development. Application of new technology such as next-generation sequencing and cryo-electron microscopy also provides valuable insights into AMR. In this Special Issue we seek manuscript submissions that further our understanding of the molecular mechanisms of resistance in staphylococci. Submissions addressing resistance to non-pharmaceutical treatments such as phage therapy are also welcomed.

Guest Editors

Dr. Jhih-Hang Jiang

Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC, Australia

Dr. Xenia Kostoulas

Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC, Australia

Deadline for manuscript submissions

closed (1 October 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/56714

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)